SCHEMBL6800569

SCHEMBL6800569

CN1CCN(c2cc3c(cc2F)c(=O)n(OCc2ccccc2)c(=O)n3-c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 2/20 0.41
TRPV4 Q9HBA0 4/20 0.41
DRD3 P35462 1/20 0.39
GRM5 P41594 1/20 0.38
THRB P10828 2/20 0.38
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802535 0.92 TRPV4 (0.42) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6800538 0.92 THRB (0.41) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6801040 0.91 ALDH1A1 (0.40) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6807024 0.90 ALDH1A1 (0.43) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6797098 0.90 ALDH1A1 (0.39) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6800773 0.88 HTR7 (0.44) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL6797472 0.85 THRB (0.39) LMNAALDH1A1GRM5THRBPOLB
SCHEMBL6795485 0.85 ALDH1A1 (0.40) MEN1KMT2ALMNAALDH1A1THRB
SCHEMBL6801065 0.84 ALDH1A1 (0.41) MEN1KMT2AALDH1A1KDM4EGRM5
SCHEMBL6796406 0.84 ALDH1A1 (0.47) MEN1KMT2ALMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A MEN1 2437/4885KMT2A 3798/4885LMNA 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.